KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

J Clin Oncol · 2025-Aug-20 · PMID 40623279

Panel F提取完成待 EXE 对齐验证

overall survival

FIG 2. Kaplan-Meier curves in the ITT set of EFS per IRC (A), PFS per IRC (B), DOR per IRC (C), duration of CR per IRC (D), OS based on the ITT principle (E), and OS based on two-stage accelerated failure time model (F). CR, complete response; DOR, duration of response; EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; ITT, intention-to-treat; liso-cel, lisocabtagene maraleucel; NR, not reached; OS, overall survival; PFS, progression-free survival; SOC, standard of care.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.79
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T17:33:29+00:00